Roche's Tecentriq fails trial in form of urothelial cancer

Roche’s immunotherapy Tecentriq failed a late-stage clinical trial in a form of urothelial cancer, the Swiss drugmaker said on Friday.

The study evaluating Tecentriq as an after-surgery monotherapy did not meet its primary endpoint of disease-free survival compared to observation in people with muscle-invasive urothelial cancer, Roche said.